
|Videos|February 9, 2016
Dr. Maciej Michal Mrugala on the Efficacy and Further Uses of Temozolomide in Gliomas
Author(s)Maciej Michal Mrugala MD, PhD, MPH
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington
Advertisement
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington’s School of Medicine, discusses the efficacy of temozolomide in gliomas. Mrugala says temozolomide is one of the few treatments that can effectively cross the blood-brain barrier, and is more bioavailable than most other treatments.
Mrugala adds that there are currently ongoing tests to study the efficacy of temozolomide given locally in animal models. He adds there are also studies looking into placing temozolomide into a polymer, which in turn would be placed into the resection cavity as another way of administering treatment.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































